Aegerion Pharmaceuticals Inc. (AEGR) Given Average Recommendation of “Hold” by Brokerages
Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) has been given a consensus recommendation of “Hold” by the six brokerages that are covering the company. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $11.33.
A number of analysts have weighed in on AEGR shares. Zacks Investment Research cut shares of Aegerion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 25th. JPMorgan Chase & Co. started coverage on shares of Aegerion Pharmaceuticals in a report on Friday. They set a “hold” rating on the stock.
Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) opened at 1.83 on Wednesday. The firm’s market cap is $54.01 million. Aegerion Pharmaceuticals has a 52 week low of $1.23 and a 52 week high of $10.85. The company has a 50 day moving average of $2.22 and a 200 day moving average of $1.87.
In other news, major shareholder Healthcare Master Fun Broadfin purchased 75,000 shares of the stock in a transaction dated Tuesday, September 13th. The stock was acquired at an average price of $1.75 per share, for a total transaction of $131,250.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.60% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. raised its position in shares of Aegerion Pharmaceuticals by 82.8% in the first quarter. Goldman Sachs Group Inc. now owns 294,691 shares of the biopharmaceutical company’s stock worth $1,090,000 after buying an additional 133,486 shares in the last quarter. Bogle Investment Management L P DE raised its position in shares of Aegerion Pharmaceuticals by 25.8% in the first quarter. Bogle Investment Management L P DE now owns 417,387 shares of the biopharmaceutical company’s stock worth $1,544,000 after buying an additional 85,670 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Aegerion Pharmaceuticals during the first quarter worth about $574,000. Eqis Capital Management Inc. raised its position in shares of Aegerion Pharmaceuticals by 3.9% in the second quarter. Eqis Capital Management Inc. now owns 87,458 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 3,255 shares in the last quarter. Finally, Artal Group S.A. bought a new position in shares of Aegerion Pharmaceuticals during the second quarter worth about $1,490,000. Institutional investors and hedge funds own 87.16% of the company’s stock.
Aegerion Pharmaceuticals Company Profile
Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.
Receive News & Stock Ratings for Aegerion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.